Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Elizabeth M Adkins,1 Lindsay Nicholson,1 David Floyd,1 Mark Ratcliffe,1 Helene Chevrou-Severac2 1PHMR, London, UK; 2Takeda Pharmaceuticals AG, Zurich, Switzerland Abstract: Orphan drugs (ODs) are intended for the diagnosis, prevention, or treatment of rare diseases. Many cancer subtypes, including a...

Full description

Bibliographic Details
Main Authors: Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H
Format: Article
Language:English
Published: Dove Medical Press 2017-06-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Orphan drugs
health technology assessment
oncology
rare cancers
Online Access:https://www.dovepress.com/oncology-drugs-for-orphan-indications-how-are-hta-processes-evolving-f-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/oncology-drugs-for-orphan-indications-how-are-hta-processes-evolving-f-peer-reviewed-article-CEOR

Similar Items